{"id":45585,"date":"2025-11-03T14:02:41","date_gmt":"2025-11-03T06:02:41","guid":{"rendered":"https:\/\/flcube.com\/?p=45585"},"modified":"2025-11-03T14:02:42","modified_gmt":"2025-11-03T06:02:42","slug":"astellas-pharma-posts-10-revenue-rise-and-54-core-operating%e2%80%91profit-surge-in-h1-fy2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45585","title":{"rendered":"Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating\u2011Profit Surge in H1\u202fFY2025"},"content":{"rendered":"\n<p><strong>Astellas Pharma Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4503:TYO\">TYO: 4503<\/a>) released its consolidated six\u2011month results for fiscal year\u202f2025 (1\u202fApr\u202f2025\u202f\u2013\u202f30\u202fSep\u202f2025). The Japanese\u2011based pharmaceutical group delivered <strong>JPY\u202f1,030.1\u202fbn<\/strong> (\u2248\u202fUSD\u202f6.69\u202fbn) in net revenue, up <strong>10.1\u202f% YoY<\/strong>, and <strong>Core Operating Profit of JPY\u202f282.6\u202fbn<\/strong> (\u2248\u202fUSD\u202f1.84\u202fbn), a <strong>54.4\u202f% YoY<\/strong> increase.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-revenue-breakdown-by-region-h1-fy2025\">Revenue Breakdown by Region (H1\u202fFY2025)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Revenue (JPY\u202fbn)<\/th><th>YoY Growth<\/th><\/tr><\/thead><tbody><tr><td>Japan<\/td><td>142.9<\/td><td>+7.0\u202f%<\/td><\/tr><tr><td>United States<\/td><td>457.1<\/td><td>+9.0\u202f%<\/td><\/tr><tr><td>Established Markets* (Europe, Canada, etc.)<\/td><td>264.9<\/td><td>+10.4\u202f%<\/td><\/tr><tr><td>China (Mainland &amp; Hong\u202fKong)<\/td><td>49.7<\/td><td>+32.0\u202f%<\/td><\/tr><tr><td>International Markets\u2020 (LatAm, MEA, SEA, South\u202fAsia, Russia, South\u202fKorea, Taiwan, Australia, etc.)<\/td><td>111.5<\/td><td>+11.5\u202f%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>*Europe, Canada and other mature markets.<br>\u2020All other territories not listed above.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-brand-performance\">Strategic Brand Performance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic\u2011Brand revenue:<\/strong> >\u202fJPY\u202f220\u202fbn, <strong>+43\u202f% YoY<\/strong>.<\/li>\n\n\n\n<li><strong>Padcev (enfortumab vedotin)<\/strong> \u2013 JPY\u202f102.5\u202fbn (<strong>+35.9\u202f%<\/strong>)<\/li>\n\n\n\n<li><strong>Izervay (avacincaptad pegol)<\/strong> \u2013 JPY\u202f34.1\u202fbn (<strong>+21.4\u202f%<\/strong>)<\/li>\n\n\n\n<li><strong>Veozah\/Veoza (fezolinetant)<\/strong> \u2013 JPY\u202f22.9\u202fbn (<strong>+54.7\u202f%<\/strong>)<\/li>\n\n\n\n<li><strong>Vyloy (zolbetuximab)<\/strong> \u2013 JPY\u202f26.6\u202fbn (<strong>+>100\u202f%<\/strong>)<\/li>\n\n\n\n<li><strong>Xospata (gilteritinib)<\/strong> \u2013 JPY\u202f34.4\u202fbn (stable)<\/li>\n\n\n\n<li><strong>Xtandi (enzalutamide)<\/strong> \u2013 JPY\u202f477.0\u202fbn (<strong>+5.6\u202f%<\/strong>)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-full-year-fy2025-guidance-update\">Full\u2011Year FY2025 Guidance Update<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Prior Guidance<\/th><th>Revised Guidance<\/th><\/tr><\/thead><tbody><tr><td>Net Sales<\/td><td>JPY\u202f1,930.0\u202fbn<\/td><td><strong>JPY\u202f2,030.0\u202fbn<\/strong><\/td><\/tr><tr><td>Core Operating Profit<\/td><td>JPY\u202f160.0\u202fbn<\/td><td><strong>JPY\u202f240.0\u202fbn<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Management attributed the upward revision to <strong>strong U.S. performance, accelerated growth in China, and double\u2011digit gains from the newly launched strategic brands<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties, including future sales, profitability, regulatory approvals and market conditions. Actual results may differ materially from those expressed herein.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Astellas Pharma Inc. (TYO: 4503) released its consolidated six\u2011month results for fiscal year\u202f2025 (1\u202fApr\u202f2025\u202f\u2013\u202f30\u202fSep\u202f2025). The&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45586,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[353,27,1177],"class_list":["post-45585","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-astellas-pharma","tag-finanical-reports","tag-tyo-4503"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating\u2011Profit Surge in H1\u202fFY2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Astellas Pharma Inc. (TYO: 4503) released its consolidated six\u2011month results for fiscal year\u202f2025 (1\u202fApr\u202f2025\u202f\u2013\u202f30\u202fSep\u202f2025). The Japanese\u2011based pharmaceutical group delivered JPY\u202f1,030.1\u202fbn (\u2248\u202fUSD\u202f6.69\u202fbn) in net revenue, up 10.1\u202f% YoY, and Core Operating Profit of JPY\u202f282.6\u202fbn (\u2248\u202fUSD\u202f1.84\u202fbn), a 54.4\u202f% YoY increase.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45585\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating\u2011Profit Surge in H1\u202fFY2025\" \/>\n<meta property=\"og:description\" content=\"Astellas Pharma Inc. (TYO: 4503) released its consolidated six\u2011month results for fiscal year\u202f2025 (1\u202fApr\u202f2025\u202f\u2013\u202f30\u202fSep\u202f2025). The Japanese\u2011based pharmaceutical group delivered JPY\u202f1,030.1\u202fbn (\u2248\u202fUSD\u202f6.69\u202fbn) in net revenue, up 10.1\u202f% YoY, and Core Operating Profit of JPY\u202f282.6\u202fbn (\u2248\u202fUSD\u202f1.84\u202fbn), a 54.4\u202f% YoY increase.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45585\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T06:02:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-03T06:02:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0307.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45585#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45585\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating\u2011Profit Surge in H1\u202fFY2025\",\"datePublished\":\"2025-11-03T06:02:41+00:00\",\"dateModified\":\"2025-11-03T06:02:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45585\"},\"wordCount\":225,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45585#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0307.webp\",\"keywords\":[\"Astellas Pharma\",\"Finanical Reports\",\"TYO: 4503\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45585#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45585\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45585\",\"name\":\"Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating\u2011Profit Surge in H1\u202fFY2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45585#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45585#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0307.webp\",\"datePublished\":\"2025-11-03T06:02:41+00:00\",\"dateModified\":\"2025-11-03T06:02:42+00:00\",\"description\":\"Astellas Pharma Inc. (TYO: 4503) released its consolidated six\u2011month results for fiscal year\u202f2025 (1\u202fApr\u202f2025\u202f\u2013\u202f30\u202fSep\u202f2025). The Japanese\u2011based pharmaceutical group delivered JPY\u202f1,030.1\u202fbn (\u2248\u202fUSD\u202f6.69\u202fbn) in net revenue, up 10.1\u202f% YoY, and Core Operating Profit of JPY\u202f282.6\u202fbn (\u2248\u202fUSD\u202f1.84\u202fbn), a 54.4\u202f% YoY increase.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45585#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45585\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45585#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0307.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0307.webp\",\"width\":1080,\"height\":608,\"caption\":\"Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating\u2011Profit Surge in H1\u202fFY2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45585#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating\u2011Profit Surge in H1\u202fFY2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating\u2011Profit Surge in H1\u202fFY2025 - Insight, China&#039;s Pharmaceutical Industry","description":"Astellas Pharma Inc. (TYO: 4503) released its consolidated six\u2011month results for fiscal year\u202f2025 (1\u202fApr\u202f2025\u202f\u2013\u202f30\u202fSep\u202f2025). The Japanese\u2011based pharmaceutical group delivered JPY\u202f1,030.1\u202fbn (\u2248\u202fUSD\u202f6.69\u202fbn) in net revenue, up 10.1\u202f% YoY, and Core Operating Profit of JPY\u202f282.6\u202fbn (\u2248\u202fUSD\u202f1.84\u202fbn), a 54.4\u202f% YoY increase.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45585","og_locale":"en_US","og_type":"article","og_title":"Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating\u2011Profit Surge in H1\u202fFY2025","og_description":"Astellas Pharma Inc. (TYO: 4503) released its consolidated six\u2011month results for fiscal year\u202f2025 (1\u202fApr\u202f2025\u202f\u2013\u202f30\u202fSep\u202f2025). The Japanese\u2011based pharmaceutical group delivered JPY\u202f1,030.1\u202fbn (\u2248\u202fUSD\u202f6.69\u202fbn) in net revenue, up 10.1\u202f% YoY, and Core Operating Profit of JPY\u202f282.6\u202fbn (\u2248\u202fUSD\u202f1.84\u202fbn), a 54.4\u202f% YoY increase.","og_url":"https:\/\/flcube.com\/?p=45585","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-03T06:02:41+00:00","article_modified_time":"2025-11-03T06:02:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0307.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45585#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45585"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating\u2011Profit Surge in H1\u202fFY2025","datePublished":"2025-11-03T06:02:41+00:00","dateModified":"2025-11-03T06:02:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45585"},"wordCount":225,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45585#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0307.webp","keywords":["Astellas Pharma","Finanical Reports","TYO: 4503"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45585#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45585","url":"https:\/\/flcube.com\/?p=45585","name":"Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating\u2011Profit Surge in H1\u202fFY2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45585#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45585#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0307.webp","datePublished":"2025-11-03T06:02:41+00:00","dateModified":"2025-11-03T06:02:42+00:00","description":"Astellas Pharma Inc. (TYO: 4503) released its consolidated six\u2011month results for fiscal year\u202f2025 (1\u202fApr\u202f2025\u202f\u2013\u202f30\u202fSep\u202f2025). The Japanese\u2011based pharmaceutical group delivered JPY\u202f1,030.1\u202fbn (\u2248\u202fUSD\u202f6.69\u202fbn) in net revenue, up 10.1\u202f% YoY, and Core Operating Profit of JPY\u202f282.6\u202fbn (\u2248\u202fUSD\u202f1.84\u202fbn), a 54.4\u202f% YoY increase.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45585#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45585"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45585#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0307.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0307.webp","width":1080,"height":608,"caption":"Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating\u2011Profit Surge in H1\u202fFY2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45585#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating\u2011Profit Surge in H1\u202fFY2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0307.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45585"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45585\/revisions"}],"predecessor-version":[{"id":45587,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45585\/revisions\/45587"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45586"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}